FINANCIAL BURDEN AND IMPOVERISHMENT DUE TO CARDIOVASCULAR MEDICINES IN LOW AND MIDDLE INCOME COUNTRIES, AN ANALYSIS WITH ILLUSTRATION FROM INDIA
Candidate for the Lee B. Lusted Student Prize Competition
Health expenditures are a major reason for financial burden in low and middle income countries as these countries often lack health insurance. With the increasing incidence of non-communicable diseases, this trend is likely to worsen. We estimate the effect on poverty of purchasing cardiovascular medicines in India.
Method:
We created a treatment ladder of cardiovascular medicines with an Aspirin, Atenolol, Atorvastatin, Losartan and Hydrochlorothiazide to reflect a step-up therapy approach for cardiovascular diseases. Drug prices were Government of India mandated ceiling prices for essential medicines plus taxes. Daily per-capita expenditures obtained from the latest National Sample Survey were used as a measure of available resource. Poverty thresholds were used as set by the Planning Commission in 2013. We calculated step-wise projected incidence and intensity of impoverishment due to medicine purchase.
Result:
Daily cost of medicines at Step 1 was ₹0·13 (₹1=$0·016) with Aspirin 75 mg, in Step 2 it was ₹2·32 with addition of Atenolol 50mg, ₹8·88 in Step 3 with the addition of 10 mg of Atorvastatin, ₹11·53 in Step 4 with Losartan 25 mg and ₹12·56 in Step 5 with addition of Hydrochlorothiazide 12·5 mg. 22·7% of rural and 14·3% percent of urban Indian population is poor at the designated poverty thresholds. The need to purchase Step 2 medicines would impoverish an additional 4.7% rural and 3.3% urban population; poverty gaps would increase by 0.64% and 0.17% respectively. At step 5 the poverty ratios would increase by 36% and 15.8%; poverty gap increase would be 15% and 7.9%. Using higher doses of Atenolol, Losartan and Atorvastatin in Step 5 would increase the poverty ratios by 63.1% and 40.8%. ·
Conclusion:
Medication costs have the potential to cause impoverishment in a significant proportion of people in India. As cardiovascular disease prevalence increases, such costs are likely to be a major reason for impoverishment.
See more of: The 36th Annual Meeting of the Society for Medical Decision Making